Adult-onset Still's disease with elderly onset: results from a multicentre study.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 21 12 2021
accepted: 14 03 2022
pubmed: 18 5 2022
medline: 17 9 2022
entrez: 17 5 2022
Statut: ppublish

Résumé

In this study, we aimed at describing the clinical characteristics, life-threatening complications occurrence, and mortality of adult-onset Still's disease (AOSD) patients with elderly onset. A multicentre retrospective study of prospectively followed-up AOSD patients included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort was performed. Out of 221 assessed patients, 37 (16.7%) had an onset of the disease aged over 60 years. When compared with younger patients, these were characterised by a higher prevalence of pericarditis (p=0.008), comorbidities (p<0.0001), and mortality (p=0.023). Age predicted the presence of serositis in both univariate (HR: 1.02, 95%CI: 1.01-1.03, p=0.007) and multivariate analyses (HR: 1.02, 95%CI: 1.01-1.04, p=0.007). Age was also a significant predictor of parenchymal lung disease in both univariate (HR: 1.03, 95%CI: 1.01-1.05, p=0.017) and multivariate analyses (HR: 1.03, 95%CI: 1.00-1.05, p=0.048). Furthermore, age resulted to be a negative predictor of polycyclic pattern only in univariate analysis (HR: 0.99, 95%CI: 0.97-1.00, p=0.048). Finally, age significantly predicted the mortality in both univariate (HR: 1.03, 95%CI: 1.00-1.06, p=0.034) and multivariate analyses (HR: 1.05, 95%CI: 1.01-1.08, p=0.012). Clinical features of AOSD patients in the elderly were described in our cohort. Although the main clinical characteristics were similar comparing older and younger patients, patients aged over 60 years at disease onset were characterised by an increased prevalence of serositis, comorbidities, mostly cardiometabolic, and a higher mortality rate. Age predicted the presence of parenchymal lung disease and mortality, and it could be considered a negative prognostic factor in AOSD.

Identifiants

pubmed: 35579097
pii: 18230
doi: 10.55563/clinexprheumatol/0215kv
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1517-1525

Auteurs

Ilenia Di Cola (I)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.

Claudia Di Muzio (C)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.

Alessandro Conforti (A)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.

Daniela Iacono (D)

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Ilenia Pantano (I)

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Gelsomina Rozza (G)

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Silvia Rossi (S)

Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy.

Ludovico De Stefano (L)

Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy.

Antonio Vitale (A)

Research Centre of Systemic Auto-Inflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Centre, Rheumatology Unit, Policlinico Le Scotte, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

Francesco Caso (F)

Rheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Luisa Costa (L)

Rheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Marcella Prete (M)

Rheumatic and Systemic Autoimmune Diseases Unit, Department of Interdisciplinary Medicine (DIM), University of Bari Medical School, Bari, Italy.

Luca Navarini (L)

Rheumatology and Immunology Unit, Department of Medicine, University of Rome Campus Biomedico, Rome, Italy.

Annamaria Iagnocco (A)

Academic Rheumatology Centre, Ospedale Mauriziano, Dipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Italy.

Fabiola Atzeni (F)

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Messina, Italy.

Giuliana Guggino (G)

Rheumatology Section, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University Hospital P. Giaccone, Palermo, Italy.

Federico Perosa (F)

Rheumatic and Systemic Autoimmune Diseases Unit, Department of Interdisciplinary Medicine (DIM), University of Bari Medical School, Bari, Italy.

Luca Cantarini (L)

Research Centre of Systemic Auto-Inflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Centre, Rheumatology Unit, Policlinico Le Scotte, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

Bruno Frediani (B)

Research Centre of Systemic Auto-Inflammatory Diseases, Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Centre, Rheumatology Unit, Policlinico Le Scotte, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

Serena Bugatti (S)

Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy.

Carlomaurizio Montecucco (C)

Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy.

Francesco Ciccia (F)

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Roberto Giacomelli (R)

Rheumatology and Immunology Unit, Department of Medicine, University of Rome Campus Biomedico, Rome, Italy.

Paola Cipriani (P)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.

Piero Ruscitti (P)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy. piero.ruscitti@univaq.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH